Ciclosporin misuse/ribavirin/sofosbuvir
- PDF / 169,734 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 65 Downloads / 183 Views
1 S
Anaemia and acute renal failure: 2 case reports In a study to evaluate the sustained viral response to new Hepatitis-C virus (HCV) treatment (direct-acting antivirals) involving 39 patients, two patients [ages and sexes not stated] were described, who developed anaemia during treatment with sofosbuvir and ribavirin (1 patient) or acute renal failure following misuse of ciclosporin (the patient continued ciclosporin despite doctor’s recommendation of stopping it) (1 patient) [dosages, routes, times to reactions onsets and outcomes not stated]. Case 1: The patient, who had HCV, started receiving sofosbuvir and ribavirin. Subsequently, the patient developed anaemia. Therefore, the dose of ribavirin was reduced. Forty-five days after initiation of sofosbuvir and ribavirin, the HCV-RNA became negative. The patient stopped the treatment after the 4th month of it’s initiation. Case 2: The patient, who had HCV, started receiving ciclosporin [cyclosporine]. On 28th day of ciclosporin therapy, the HCV-RNA was found to be negative. The patient was advised to discontinue ciclosporin. Despite the doctor’s instructions to stop ciclosporin use, the patient continued taking ciclosporin (drug misuse). Subsequently, the patient developed ciclosporin-related acute renal failure. The patient’s ciclosporin therapy was therefore stopped. Coskuner SA, et al. Sustained viral response to new HCV treatment (direct-acting antivirals) in the second year of treatment and evaluation of side effects. Turkish Journal of 803507366 Gastroenterology 30 (Suppl. 1): S56-S57 (plus poster) abstr. P-030, No. 1, Apr 2019. Available from: URL: http://doi.org/10.5152/tjg.2019.36 [abstract]
0114-9954/20/1826-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 17 Oct 2020 No. 1826
Data Loading...
